Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

DCC (deleted in colorectal carcinoma)

Written2010-01Sarah Derks, Manon van Engeland
Department of Internal Medicine, Maastricht University Medical Center, PO BOX 616, 6200 MD Maastricht, The Netherlands (SD); Department of Pathology, Maastricht University Medical Center, PO BOX 616, 6200 MD Maastricht, The Netherlands (MvE)

(Note : for Links provided by Atlas : click)

Identity

Alias_namesDCC subclass
member 1
Alias_symbol (synonym)IGDCC1
NTN1R1
Other aliasCRC18
CRCR1
HGNC (Hugo) DCC
LocusID (NCBI) 1630
Atlas_Id 331
Location 18q21.2  [Link to chromosome band 18q21]
Location_base_pair Starts at 52340172 and ends at 53535903 bp from pter ( according to hg19-Feb_2009)  [Mapping DCC.png]
Local_order Between RKHD2 and MBD2 genes.
 
  Diagram of chromosomal region 18q21.
Fusion genes
(updated 2017)		Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
CYB5A (18q22.3) / DCC (18q21.2)DCC (18q21.2) / DCC (18q21.2)KCNMA1 (10q22.3) / DCC (18q21.2)
KIAA1328 (18q12.2) / DCC (18q21.2)ROCK1 (18q11.1) / DCC (18q21.2)

DNA/RNA

 
  Diagram of the DCC gene. Blue boxes represent exons.
Description The DCC gene is composed of 29 exons spanning in a region of 1.2 million bp. The promoter contains a CpG island located -72 bp to +217 bp relative to the transcription startsite.
Transcription The complete transcribed mRNA is 5693 bp long.

Splice variants:
13 splice variants have been documented.

Protein

 
  Diagram of the DCC protein. Ig: immunoglobulin, Fn: fibronectin-type III, TM: transmembrane domain, ICD: intracellular domain.
Description DCC encodes a 158.5 kDa Type I membrane protein of 1447 amino acids with an extracellular (1100 amino acids), transmembrane and cytoplasmic (325 amino acids) domain. The extracellular domain includes four immunoglobulin-like domains and six fibronectin type III-like motifs. The cytoplasmic domain is composed of three conserved domains named P1, P2 and P3.
Expression Expression is detected in many tissues (testis, lung, colon, esophagus, skeletal muscle) but is highest in normal brain tissue. Most tissues express low levels of transcripts and proteins.
Localisation Cell surface.
Function DCC is a member of the immunoglobulin superfamily of cell adhesion molecules and acts as a transmembrane dependence receptor for netrins, key factors in the regulation of axon guidance during development of the central nerve system.
In response to netrin-1, DCC becomes tyrosine phosphorylated, localizes to lipid rafts and selectively interacts with the Src family kinases Fyn and Lck to mediate axon attraction.
Furthermore DCC induces apoptosis when unbound to its ligand netrin-1. The DCC cytoplasmic domain is required for the induction of apoptosis and contains a caspase cleavage site which is recognized by caspase 3 in vitro. Upstream of the caspase cleavage domain a proapoptotic domain named addiction dependence domain (ADD) is located, which interacts with caspase 9 in the absence of Netrin-1 and binds DCC-interacting protein-13a (DIP13-a) to mediate DCC-induced cell death.
DCCs downstream effects involve MAPK activation and subsequent activation of the transcription factor Elk-1 and SRE regulated gene expression.
Homology DCC has a homolog in mammals named neogin and is conserved in chimpanzee, dog, cow, mouse, rat, zebrafish, Caenorhabditis elegans (UNC40) and Drosophila (Frazzled).

Mutations

Somatic DCC mutations rarely occur in cancer. In colorectal cancer (CRC) the most common somatic mutations are 120 to 300 bp expansions in a dinucleotide repeat tract located in an intron region immediately downstream of exon 7. Expansions are present in 10-15 % of CRCs which are cancers with microsatellite instability.

Implicated in

Note
  
Entity Colorectal cancer
Note By regulating apoptosis in the absence of netrin-1, DCC is a conditional tumor suppressor. In normal conditions, DCC induced apoptosis limits cellular lifespan in the intestinal crypt and thereby inhibits the initiation of malignant transformation. Transfection of DCC cDNA into a human cell line lacking DCC expression suppresses tumor growth and results in apoptosis and cell cycle arrest.
DCC is located on chromosomal region 18q21-pter which is affected by loss of heterozygosity (LOH) which is associated with reduced DCC expression in approximately 70% of colorectal cancers.
Although DCC mutation is rare, DCC promoter CpG island methylation occurs in about 80% of CRCs.
Prognosis Absent DCC expression is a strong predictor of poor survival in stage II and stage III CRCs. In patients with stage II disease decreased DCC expression is associated with a five-year survival rate of 61.6% versus 94.3% in DCC expressing stage II CRCs. In patients with stage III disease, the respective survival rates are 59.3 percent and 33.2 percent. LOH of 18q21 alone was also associated with poor prognosis and risk of metastasis in some studies although this association was not observed by others.
Furthermore 18q LOH is associated with decreases responsiveness to fluorouracil-based adjuvant chemotherapy in stage III CRC.
Oncogenesis LOH of chromosome 18q21 profoundly occurs in progressed adenomas and colorectal carcinomas and is present in about 100% of hepatic metastasis but rarely occurs in early stage lesions. The same accounts for DCC promoter CpG island methylation which is present in 80% of adenomas and carcinomas and in only 23% of normal colon tissues.
  
  
Entity Gastric cancer
Note Reduced DCC mRNA expression is observed in 52% of gastric cancers, being present in 72% of intestinal type gastric cancers and in 17% of infiltrative type gastric cancers.
LOH of 18q21 occurs in 30% of intestinal type gastric cancers and is an infrequent event in early or advanced gastric cancer.
Oncogenesis All liver metastasis of gastric carcinomas showed reduced DCC expression.
  
  
Entity Head and neck squamous cell carcinoma (HNSCC)
Note DCC promoter CpG island methylation occurs in 75% of HNSCC. Restoration of DCC expression (by transfection) led to inhibition of cell growth in HNSCC cell lines.
Prognosis LOH of chromosomal region 18q21 occurs in 40% of HNSCC and is associated with poor patient survival.
  
  
Entity Esophageal cancer
Note 18q21 LOH occurs in 23% of esophageal squamous cell carcinomas (ESCC). DCC promoter CpG island methylation occurs in 74% of primary ESCCs in a cancer-specific manner.
Sixty-nine percent of esophageal adenocarcinomas show LOH of 18q21.
Oncogenesis 18q21 LOH occurs in 32% of barrets mucosae, 42% of low-grade dysplastic lesions, 73% of high grade dysplastic lesions and 69% of adenocarcinomas.
  
  
Entity Glioma
Note DCC expression is reduced in 66% of high-grade astrocytomas, 53% of secondary glioblastomas (progressed for low-grade astrocytomas) and 23% of de novo glioblastoma.
DCC expression is reduced in 88% of glioblastoma multiforme.
Oncogenesis Only a minority (6%) of low-grade astrocytomas show reduced DCC expression, whereas high-grade tumors show reduces DCC expression in 66% of cases.
  
  
Entity Neuroblastoma
Note Reduced DCC expression and 18q21 LOH occurs in 25-40% and 31% of primary neuroblastomas respectively.
Oncogenesis In neuroblastomas decreased DCC expression increases from 25% in stage 1-3 to 72% in stage 4 disease to 81% in metastatic disease.
  
  
Entity Hematologic malignancies/Lymphoma
Note DCC is inactivated in 30% of acute leukemias in 25% of chronic myelogenous leukemias (CML) and in 53% of non Hodgkins lymphoma.
In 18% of follicle centre cell lymphoma LOH of DCC is observed.
  
  
Entity Bladder cancer
Note LOH of 18q21 occurs in 36% of bladder carcinomas and 33% of human bladder transitional cell carcinomas (TCCs).
  
  
Entity Breast cancer
Note DCC expression is reduced in 40-55.6% of primary breast cancer.
Prognosis DCC expression is associated with longer relapse free and overall survival.
  
  
Entity Prostate cancer
Note Eighty-five percent of prostate cancers exhibit decrease DCC expression compared to normal tissue. 18q21 LOH occurs in 26-31% prostate cancers.
  
  
Entity Renal cancer
Note DCC protein expression is reduced in 40% of clear cell renal cell carcinomas (cRCC) and LOH of 18q21 occurs in 19% of cRCC.
18q21 LOH is observed in 20% of nephroblastomas.
Prognosis Decreased DCC protein expression occurred more frequently in patients who died from the disease (63%) compared to patients who did not (36%). 18q21 LOH in nephroblastomas is associated with poor prognosis.
  
  
Entity Ovarian cancer
Note DCC mRNA expression is reduced in 60% of epithelial ovarian cancer and in 50% of serous ovarian cancers.
Prognosis Reduced DCC expression is associated with poor patient outcome in epithelial ovarian cancer which is also observed in a cohort treated with combined chemotherapy platinum-paclitaxel.
Oncogenesis Reduces DCC mRNA expression is reported in only 10% of ovarian adenomas and 6% of borderline tumors compared with 60% in ovarian carcinomas.
  

Bibliography

Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with beta-catenin levels and outcome in patients with epithelial ovarian cancer.
Bamias A, Yu Z, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA, Psyrri A.
Ann Oncol. 2006 Dec;17(12):1797-802. Epub 2006 Sep 13.
PMID 16971669
 
Prognostic significance of the deleted in colorectal cancer gene protein expression in high-risk resected gastric carcinoma.
Bamias AT, Bai MC, Agnantis NJ, Michael MC, Alamanos YP, Stefanaki SV, Razi ED, Skarlos DV, Kappas AM, Pavlidis NA.
Cancer Invest. 2003 Jun;21(3):333-40.
PMID 12901278
 
Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma.
Brewster SF, Browne S, Brown KW.
J Urol. 1994 Apr;151(4):1073-7.
PMID 7510345
 
Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM-1 and DCC tumor suppressor genes on the long arm of chromosome 18.
Buschges R, Bostrom J, Wolter M, Blaschke B, Weber RG, Lichter P, Collins VP, Reifenberger G.
Int J Cancer. 2001 May 15;92(4):551-4.
PMID 11304690
 
Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer.
Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR.
Gastroenterology. 1998 Jun;114(6):1188-95.
PMID 9609755
 
Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma.
Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, Zhao M, Jeronimo C, Henrique R, Nayak CS, Park HL, Brait MR, Liu C, Zhou S, Koch W, Fazio VM, Ratovitski E, Trink B, Westra W, Sidransky D, Moon CS, Califano JA.
Cancer Res. 2006 Oct 1;66(19):9401-7.
PMID 17018594
 
The DCC gene: structural analysis and mutations in colorectal carcinomas.
Cho KR, Oliner JD, Simons JW, Hedrick L, Fearon ER, Preisinger AC, Hedge P, Silverman GA, Vogelstein B.
Genomics. 1994 Feb;19(3):525-31.
PMID 8188295
 
DCC protein expression in clear cell renal cell carcinoma.
Dekel Y, Kugel V, Livne PM, Gal R, Koren R.
BJU Int. 2004 Apr;93(6):867-9.
PMID 15050007
 
Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21.
Derks S, Bosch LJ, Niessen HE, Moerkerk PT, van den Bosch SM, Carvalho B, Mongera S, Voncken JW, Meijer GA, de Bruine AP, Herman JG, van Engeland M.
Carcinogenesis. 2009 Jun;30(6):1041-8. Epub 2009 Mar 27.
PMID 19329758
 
Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation.
Forcet C, Stein E, Pays L, Corset V, Llambi F, Tessier-Lavigne M, Mehlen P.
Nature. 2002 May 23;417(6887):443-7. Epub 2002 May 1.
PMID 11986622
 
Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes.
Fujita M, Enomoto T, Murata Y.
Mol Cell Endocrinol. 2003 Apr 28;202(1-2):97-9. (REVIEW)
PMID 12770737
 
Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas.
Gao X, Honn KV, Grignon D, Sakr W, Chen YQ.
Cancer Res. 1993 Jun 15;53(12):2723-7.
PMID 8504411
 
Deletion mapping of 18q in conventional renal cell carcinoma.
Hirata H, Matsuyama H, Matsumoto H, Korenaga Y, Ohmi C, Sakano S, Yoshihiro S, Naito K.
Cancer Genet Cytogenet. 2005 Dec;163(2):101-5.
PMID 16337851
 
Reduced expression of APC and DCC gene protein in breast cancer.
Ho KY, Kalle WH, Lo TH, Lam WY, Tang CM.
Histopathology. 1999 Sep;35(3):249-56.
PMID 10469217
 
Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers.
Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, McDaniel TK, Newkirk C, Resau JH, Sridhara R, Reid BJ, Meltzer SJ.
Cancer Res. 1992 Dec 1;52(23):6525-30.
PMID 1423299
 
Allelic loss of chromosome 18q and prognosis in colorectal cancer.
Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Hamilton SR.
N Engl J Med. 1994 Jul 28;331(4):213-21.
PMID 8015568
 
Expression of DCC and netrin-1 in normal human endometrium and its implication in endometrial carcinogenesis.
Kato HD, Kondoh H, Inoue T, Asanoma K, Matsuda T, Arima T, Kato K, Yoshikawa T, Wake N.
Gynecol Oncol. 2004 Nov;95(2):281-9.
PMID 15491747
 
The DCC gene suppresses the malignant phenotype of transformed human epithelial cells.
Klingelhutz AJ, Hedrick L, Cho KR, McDougall JK.
Oncogene. 1995 Apr 20;10(8):1581-6.
PMID 7731713
 
The expression of DCC protein in female breast cancer.
Koren R, Dekel Y, Sherman E, Weissman Y, Dreznik Z, Klein B, Gal R.
Breast Cancer Res Treat. 2003 Jul;80(2):215-20.
PMID 12908825
 
Quantification of expression of netrins, slits and their receptors in human prostate tumors.
Latil A, Chene L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P, Cussenot O.
Int J Cancer. 2003 Jan 20;103(3):306-15.
PMID 12471613
 
Mediation of the DCC apoptotic signal by DIP13 alpha.
Liu J, Yao F, Wu R, Morgan M, Thorburn A, Finley RL Jr, Chen YQ.
J Biol Chem. 2002 Jul 19;277(29):26281-5. Epub 2002 May 14.
PMID 12011067
 
Netrin-1 acts as a survival factor via its receptors UNC5H and DCC.
Llambi F, Causeret F, Bloch-Gallego E, Mehlen P.
EMBO J. 2001 Jun 1;20(11):2715-22.
PMID 11387206
 
Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives.
Marra G, Boland CR.
J Natl Cancer Inst. 1995 Aug 2;87(15):1114-25. (REVIEW)
PMID 7674315
 
Netrin-1 controls colorectal tumorigenesis by regulating apoptosis.
Mazelin L, Bernet A, Bonod-Bidaud C, Pays L, Arnaud S, Gespach C, Bredesen DE, Scoazec JY, Mehlen P.
Nature. 2004 Sep 2;431(7004):80-4.
PMID 15343335
 
The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis.
Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE.
Nature. 1998 Oct 22;395(6704):801-4.
PMID 9796814
 
Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis.
Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y.
Cancer Res. 1994 Jun 1;54(11):3007-10.
PMID 8187090
 
Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer.
Miyamoto H, Shuin T, Ikeda I, Hosaka M, Kubota Y.
J Urol. 1996 Apr;155(4):1444-7.
PMID 8632608
 
DCC promoter hypermethylation in esophageal squamous cell carcinoma.
Park HL, Kim MS, Yamashita K, Westra W, Carvalho AL, Lee J, Jiang WW, Baek JH, Liu J, Osada M, Moon CS, Califano JA, Mori M, Sidransky D.
Int J Cancer. 2008 Jun 1;122(11):2498-502.
PMID 18302152
 
Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck.
Pearlstein RP, Benninger MS, Carey TE, Zarbo RJ, Torres FX, Rybicki BA, Dyke DL.
Genes Chromosomes Cancer. 1998 Apr;21(4):333-9.
PMID 9559345
 
DCC tumor suppressor gene is inactivated in hematologic malignancies showing monosomy 18.
Porfiri E, Secker-Walker LM, Hoffbrand AV, Hancock JF.
Blood. 1993 May 15;81(10):2696-701.
PMID 8490178
 
DCC (deleted in colorectal cancer) inactivation in hematological malignancies.
Porfiri E.
Leuk Lymphoma. 1995 Jun;18(1-2):69-72. (REVIEW)
PMID 8580831
 
Microsatellite analysis of the DCC gene in nephroblastomas: pathologic correlations and prognostic implications.
Ramburan A, Chetty R, Hadley GP, Naidoo R, Govender D.
Mod Pathol. 2004 Jan;17(1):89-95.
PMID 14631365
 
Allele imbalance at tumour suppressor loci during the indolent phase of follicle centre cell lymphoma.
Randerson J, Cawkwell L, Jack AS, Child AJ, Shiach CR, Lewis F, Johnson P, Evans P, Barrans S, Morgan GJ.
Leuk Lymphoma. 1996 Jun;22(1-2):113-7, follow. 186, color plate X.
PMID 8724537
 
Loss of DCC expression in neuroblastoma is associated with disease dissemination.
Reale MA, Reyes-Mugica M, Pierceall WE, Rubinstein MC, Hedrick L, Cohn SL, Nakagawara A, Brodeur GM, Fearon ER.
Clin Cancer Res. 1996 Jul;2(7):1097-102.
PMID 9816273
 
Tyrosine phosphorylation of netrin receptors in netrin-1 signaling.
Ren XR, Hong Y, Feng Z, Yang HM, Mei L, Xiong WC.
Neurosignals. 2008;16(2-3):235-45. Epub 2008 Feb 5.
PMID 18253061
 
Status of deleted in colorectal cancer gene expression correlates with neuroblastoma metastasis.
Reyes-Mugica M, Lin P, Yokota J, Reale MA.
Lab Invest. 1998 Jun;78(6):669-75.
PMID 9645757
 
Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression.
Saegusa M, Machida D, Okayasu I.
Br J Cancer. 2000 Feb;82(3):571-8.
PMID 10682668
 
Expression of the tumor suppressor gene DCC in human gliomas.
Scheck AC, Coons SW.
Cancer Res. 1993 Dec 1;53(23):5605-9.
PMID 8242611
 
The DCC protein and prognosis in colorectal cancer.
Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, Jessup JM, Loda M, Summerhayes IC.
N Engl J Med. 1996 Dec 5;335(23):1727-32.
PMID 8929264
 
Allelotype of neuroblastoma.
Takita J, Hayashi Y, Kohno T, Shiseki M, Yamaguchi N, Hanada R, Yamamoto K, Yokota J.
Oncogene. 1995 Nov 2;11(9):1829-34.
PMID 7478611
 
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR.
N Engl J Med. 2001 Apr 19;344(16):1196-206.
PMID 11309634
 
Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection.
Wu MS, Shun CT, Wang HP, Sheu JC, Lee WJ, Wang TH, Lin JT.
Gastroenterology. 1997 May;112(5):1457-65.
PMID 9136822
 
Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region.
Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR.
Am J Pathol. 1998 Jul;153(1):287-94.
PMID 9665490
 
Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma.
Younes A, Zhao S, Jendiroba D, Kleine HD, Cabanillas F, Andreeff M.
Blood. 1995 May 15;85(10):2813-6.
PMID 7742542
 

Citation

This paper should be referenced as such :
Derks, S ; van, Engeland M
DCC (deleted in colorectal carcinoma)
Atlas Genet Cytogenet Oncol Haematol. 2010;14(10):845-907.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/DCCID331ch18q21.html

Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 5 ]
  Colon: Colorectal adenocarcinoma
Bone: Osteosarcoma
t(18;18)(q11;q21) ROCK1/DCC
t(18;18)(q12;q21) KIAA1328/DCC
t(18;18)(q21;q22) CYB5A/DCC

External links

Nomenclature
HGNC (Hugo)DCC   2701
LRG (Locus Reference Genomic)LRG_1107
Cards
AtlasDCCID331ch18q21
Entrez_Gene (NCBI)DCC  1630  DCC netrin 1 receptor
AliasesCRC18; CRCR1; HGPPS2; IGDCC1; 
MRMV1; NTN1R1
GeneCards (Weizmann)DCC
Ensembl hg19 (Hinxton)ENSG00000187323 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000187323 [Gene_View]  ENSG00000187323 [Sequence]  chr18:52340172-53535903 [Contig_View]  DCC [Vega]
ICGC DataPortalENSG00000187323
TCGA cBioPortalDCC
AceView (NCBI)DCC
Genatlas (Paris)DCC
WikiGenes1630
SOURCE (Princeton)DCC
Genetics Home Reference (NIH)DCC
Genomic and cartography
GoldenPath hg38 (UCSC)DCC  -     chr18:52340172-53535903 +  18q21.2   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)DCC  -     18q21.2   [Description]    (hg19-Feb_2009)
EnsemblDCC - 18q21.2 [CytoView hg19]  DCC - 18q21.2 [CytoView hg38]
Mapping of homologs : NCBIDCC [Mapview hg19]  DCC [Mapview hg38]
OMIM114500   120470   133239   157600   617542   
Gene and transcription
Genbank (Entrez)AK302643 AK310385 AW949550 BC036524 M32292
RefSeq transcript (Entrez)NM_005215
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)DCC
Cluster EST : UnigeneHs.162025 [ NCBI ]
CGAP (NCI)Hs.162025
Alternative Splicing GalleryENSG00000187323
Gene ExpressionDCC [ NCBI-GEO ]   DCC [ EBI - ARRAY_EXPRESS ]   DCC [ SEEK ]   DCC [ MEM ]
Gene Expression Viewer (FireBrowse)DCC [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevestigatorExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)1630
GTEX Portal (Tissue expression)DCC
Human Protein AtlasENSG00000187323-DCC [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP43146   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP43146  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP43146
Splice isoforms : SwissVarP43146
PhosPhoSitePlusP43146
Domaine pattern : Prosite (Expaxy)FN3 (PS50853)    IG_LIKE (PS50835)   
Domains : Interpro (EBI)DCC    FN3_dom    FN3_sf    Ig-like_dom    Ig-like_dom_sf    Ig-like_fold    Ig_I-set    Ig_sub    Ig_sub2    Neogenin_C   
Domain families : Pfam (Sanger)fn3 (PF00041)    I-set (PF07679)    Neogenin_C (PF06583)   
Domain families : Pfam (NCBI)pfam00041    pfam07679    pfam06583   
Domain families : Smart (EMBL)FN3 (SM00060)  IG (SM00409)  IGc2 (SM00408)  
Conserved Domain (NCBI)DCC
DMDM Disease mutations1630
Blocks (Seattle)DCC
PDB (SRS)2ED7    2ED8    2ED9    2EDB    2EDD    2EDE    3AU4    4URT    5X83   
PDB (PDBSum)2ED7    2ED8    2ED9    2EDB    2EDD    2EDE    3AU4    4URT    5X83   
PDB (IMB)2ED7    2ED8    2ED9    2EDB    2EDD    2EDE    3AU4    4URT    5X83   
PDB (RSDB)2ED7    2ED8    2ED9    2EDB    2EDD    2EDE    3AU4    4URT    5X83   
Structural Biology KnowledgeBase2ED7    2ED8    2ED9    2EDB    2EDD    2EDE    3AU4    4URT    5X83   
SCOP (Structural Classification of Proteins)2ED7    2ED8    2ED9    2EDB    2EDD    2EDE    3AU4    4URT    5X83   
CATH (Classification of proteins structures)2ED7    2ED8    2ED9    2EDB    2EDD    2EDE    3AU4    4URT    5X83   
SuperfamilyP43146
Human Protein Atlas [tissue]ENSG00000187323-DCC [tissue]
Peptide AtlasP43146
HPRD00391
IPIIPI00016422   IPI00911076   IPI01012289   
Protein Interaction databases
DIP (DOE-UCLA)P43146
IntAct (EBI)P43146
FunCoupENSG00000187323
BioGRIDDCC
STRING (EMBL)DCC
ZODIACDCC
Ontologies - Pathways
QuickGOP43146
Ontology : AmiGOneuron migration  transmembrane signaling receptor activity  netrin receptor activity  protein binding  cytosol  plasma membrane  apoptotic process  axonogenesis  axon guidance  negative regulation of neuron projection development  spinal cord ventral commissure morphogenesis  axon  dorsal/ventral axon guidance  anterior/posterior axon guidance  netrin-activated signaling pathway  negative regulation of collateral sprouting  extrinsic apoptotic signaling pathway in absence of ligand  Schaffer collateral - CA1 synapse  integral component of postsynaptic density membrane  postsynaptic modulation of chemical synaptic transmission  regulation of neuron death  negative regulation of netrin-activated signaling pathway  negative regulation of dendrite development  
Ontology : EGO-EBIneuron migration  transmembrane signaling receptor activity  netrin receptor activity  protein binding  cytosol  plasma membrane  apoptotic process  axonogenesis  axon guidance  negative regulation of neuron projection development  spinal cord ventral commissure morphogenesis  axon  dorsal/ventral axon guidance  anterior/posterior axon guidance  netrin-activated signaling pathway  negative regulation of collateral sprouting  extrinsic apoptotic signaling pathway in absence of ligand  Schaffer collateral - CA1 synapse  integral component of postsynaptic density membrane  postsynaptic modulation of chemical synaptic transmission  regulation of neuron death  negative regulation of netrin-activated signaling pathway  negative regulation of dendrite development  
Pathways : KEGGAxon guidance    Pathways in cancer    Colorectal cancer   
REACTOMEP43146 [protein]
REACTOME PathwaysR-HSA-428542 [pathway]   
NDEx NetworkDCC
Atlas of Cancer Signalling NetworkDCC
Wikipedia pathwaysDCC
Orthology - Evolution
OrthoDB1630
GeneTree (enSembl)ENSG00000187323
Phylogenetic Trees/Animal Genes : TreeFamDCC
HOVERGENP43146
HOGENOMP43146
Homologs : HomoloGeneDCC
Homology/Alignments : Family Browser (UCSC)DCC
Gene fusions - Rearrangements
Fusion : MitelmanCYB5A/DCC [18q22.3/18q21.2]  [t(18;18)(q21;q22)]  
Fusion : MitelmanKIAA1328/DCC [18q12.2/18q21.2]  [t(18;18)(q12;q21)]  
Fusion : MitelmanROCK1/DCC [18q11.1/18q21.2]  [t(18;18)(q11;q21)]  
Fusion PortalCYB5A 18q22.3 DCC 18q21.2 SKCM
Fusion PortalKIAA1328 18q12.2 DCC 18q21.2 BLCA
Fusion PortalROCK1 18q11.1 DCC 18q21.2 HNSC
Fusion : QuiverDCC
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerDCC [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)DCC
dbVarDCC
ClinVarDCC
1000_GenomesDCC 
Exome Variant ServerDCC
ExAC (Exome Aggregation Consortium)ENSG00000187323
GNOMAD BrowserENSG00000187323
Varsome BrowserDCC
Genetic variants : HAPMAP1630
Genomic Variants (DGV)DCC [DGVbeta]
DECIPHERDCC [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisDCC 
Mutations
ICGC Data PortalDCC 
TCGA Data PortalDCC 
Broad Tumor PortalDCC
OASIS PortalDCC [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICDCC  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDDCC
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch DCC
DgiDB (Drug Gene Interaction Database)DCC
DoCM (Curated mutations)DCC (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)DCC (select a term)
intoGenDCC
NCG5 (London)DCC
Cancer3DDCC(select the gene name)
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM114500    120470    133239    157600    617542   
Orphanet19298   
DisGeNETDCC
MedgenDCC
Genetic Testing Registry DCC
NextProtP43146 [Medical]
TSGene1630
GENETestsDCC
Target ValidationDCC
Huge Navigator DCC [HugePedia]
snp3D : Map Gene to Disease1630
BioCentury BCIQDCC
ClinGenDCC
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD1630
Chemical/Pharm GKB GenePA27170
Clinical trialDCC
Miscellaneous
canSAR (ICR)DCC (select the gene name)
Probes
Litterature
PubMed127 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineDCC
EVEXDCC
GoPubMedDCC
iHOPDCC
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Dec 10 13:54:32 CET 2018
Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.